| Display title | Chemistry:Idraparinux |
| Default sort key | Idraparinux |
| Page length (in bytes) | 7,502 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 246275 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image | Error creating thumbnail: Unable to save thumbnail to destination |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>BotanyGa |
| Date of page creation | 20:44, 5 February 2024 |
| Latest editor | imported>BotanyGa |
| Date of latest edit | 20:44, 5 February 2024 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Idraparinux sodium is an anticoagulant medication in development by Sanofi-Aventis.
It has a similar chemical structure and the same method of action as fondaparinux, but with an elimination half-life about five to six times longer (an increase from fondaparinux's 17 hours to approximately 80 hours) |
